X
[{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Cochlear Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Association for Research in Otolaryngology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Modelsat the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Update on SENS-401","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"},{"orgOrder":0,"company":"Sensorion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Sensorion"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 07, 2022
Details:
SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 01, 2022
Details:
SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss, aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 18, 2022
Details:
SENS-401 demonstrated a statistically significant effect with the high dose on pure tone audiometry (≥ 10 decibels improvement vs placebo) in Phase 2 AUDIBLE-S trial in SSNHL at Day 84 in per protocol idiopathic population (81 patients) treated with corticosteroids.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 17, 2022
Details:
SENS-401 (R-azasetron besylate), oral small molecule lead asset currently being investigated in sudden sensorineural hearing loss and cisplatin-induced ototoxicity aims to protect and preserve inner ear tissue from damage.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Association for Research in Otolaryngology
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 03, 2022
Details:
SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Cochlear Limited
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 27, 2021
Details:
The poster presented shows SENS-401 ability to yield significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma.
Lead Product(s):
R-Azasetron Besylate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: SENS-401
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 19, 2021
Details:
Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced.
Lead Product(s):
Azasetron
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 13, 2020